全文获取类型
收费全文 | 26546篇 |
免费 | 6432篇 |
国内免费 | 135篇 |
专业分类
耳鼻咽喉 | 655篇 |
儿科学 | 903篇 |
妇产科学 | 855篇 |
基础医学 | 1052篇 |
口腔科学 | 2760篇 |
临床医学 | 4538篇 |
内科学 | 6195篇 |
皮肤病学 | 599篇 |
神经病学 | 2804篇 |
特种医学 | 1289篇 |
外国民族医学 | 2篇 |
外科学 | 4232篇 |
综合类 | 194篇 |
现状与发展 | 12篇 |
预防医学 | 3354篇 |
眼科学 | 364篇 |
药学 | 495篇 |
中国医学 | 6篇 |
肿瘤学 | 2804篇 |
出版年
2024年 | 141篇 |
2023年 | 1121篇 |
2022年 | 369篇 |
2021年 | 693篇 |
2020年 | 1268篇 |
2019年 | 547篇 |
2018年 | 1396篇 |
2017年 | 1339篇 |
2016年 | 1568篇 |
2015年 | 1641篇 |
2014年 | 2055篇 |
2013年 | 2514篇 |
2012年 | 1025篇 |
2011年 | 969篇 |
2010年 | 1493篇 |
2009年 | 2051篇 |
2008年 | 975篇 |
2007年 | 757篇 |
2006年 | 868篇 |
2005年 | 673篇 |
2004年 | 551篇 |
2003年 | 501篇 |
2002年 | 451篇 |
2001年 | 554篇 |
2000年 | 434篇 |
1999年 | 522篇 |
1998年 | 561篇 |
1997年 | 531篇 |
1996年 | 576篇 |
1995年 | 435篇 |
1994年 | 332篇 |
1993年 | 316篇 |
1992年 | 332篇 |
1991年 | 288篇 |
1990年 | 267篇 |
1989年 | 284篇 |
1988年 | 267篇 |
1987年 | 251篇 |
1986年 | 214篇 |
1985年 | 201篇 |
1984年 | 178篇 |
1983年 | 169篇 |
1982年 | 136篇 |
1981年 | 118篇 |
1980年 | 94篇 |
1979年 | 120篇 |
1978年 | 76篇 |
1977年 | 111篇 |
1974年 | 88篇 |
1973年 | 85篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Maaike van Gerwen MD Naomi Alpert MS Raja Flores MD Emanuela Taioli MD PhD 《American journal of industrial medicine》2020,63(2):115-120
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of national agencies. This review compares currently existing mesothelioma registries worldwide to develop a concept model for a US real-time case capture mesothelioma registry. Five countries were identified with a mesothelioma specific registry, including Italy, France, UK, Australia, and South Korea. All, except the UK, used interviews to collect exposure data. Linkage with the national death index was available or was in future plans for all registries. The registries have limited information on treatment, quality of life, and other patient-centered outcomes such as symptoms and pain management. To thoroughly collect exposure data, “real-time” enrollment is preferable; to maximize the capture of mesothelioma cases, optimal coverage, and a simplified consent process are needed. 相似文献
4.
Chie Teramoto PHN RN MS Satoko Nagata PhD PHN RN Reiko Okamoto PhD PHN RN Ruriko Suzuki PHN RN MS Emiko Kishi PhD PHN RN Michie Nomura DSN PHN RN Noriko Jojima PHN RN MS Masumi Nishida PhD PHN RN Keiko Koide PhD PHN RN Emiko Kusano PhD PHN RN Saori Iwamoto PhD PHN RN Sachiyo Murashima PhD PHN RN 《Public health nursing (Boston, Mass.)》2015,32(6):654-661
5.
6.
7.
Katherine M. Duszynski Nicole L. Pratt John W. Lynch Jesia G. Berry Michael S. Gold 《Vaccine》2019,37(2):280-288
Objective
To determine whether differences in combination DTaP vaccine types at 2, 4 and 6?months of age were associated with mortality (all-cause or non-specific), within 30?days of vaccination.Design
Observational nationwide cohort study.Setting
Linked population data from the Australian Childhood Immunisation Register and National Death Index.Participants
Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6?months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3?million children in the 2, 4 and 6?month vaccine cohorts, respectively.Main outcome measures
Infants were evaluated for the primary outcome of all-cause mortality within 30?days. A secondary outcome was non-specific mortality (unknown cause of death) within 30?days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 ‘Sudden infant death syndrome’, R96 ‘Other sudden death, cause unknown’, R98 ‘Unattended death’, R99 ‘Other ill-defined and unspecified cause of mortality’ or where no cause of death was recorded.Results
The rate of 30?day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6?month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort.Conclusion
Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality. 相似文献8.
9.
10.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691